Danyelza

Active Ingredient(s): Naxitamab-gqgk
FDA Approved: * November 25, 2020
Pharm Company: * Y-MABS THERAPEUTICS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Danyelza Overview

Naxitamab, sold under the brand name Danyelza, is a monoclonal antibody medication used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.[2][3] The most common adverse reactions include infusion-related reactions, pain, tachycardia, vo...

Read more Danyelza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Naxitamab

Recent Danyelza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Naxitamab-gqgk or a similar ingredient: (1 result)

• NAXITAMAB